Medicare beneficiaries filling prescriptions in 2026 will face a higher upfront cost before their drug coverage kicks in. The standard Part D deductible rises to $615 next year, a $25 increase from the current $590 level, according to the Centers for Medicare and Medicaid Services. The bump arrives during a period of broader Part D redesign under the Inflation Reduction Act, which also caps total annual out-of-pocket drug spending. For the tens of millions of Americans enrolled in Part D plans, the deductible increase will shape plan comparisons during fall open enrollment later this year.
Why the $615 Part D deductible increase hits during a redesign year
The annual deductible adjustment is not discretionary. Federal law ties the Part D standard benefit parameters to the annual percentage increase in average per capita aggregate expenditures for covered Part D drugs, as spelled out in Medicare statute. When average drug spending per enrollee rises, the deductible ceiling moves with it. That formula produced the $25 jump from $590 to $615.
The timing creates a tension worth watching. CMS finalized the $615 figure in its CY 2026 Part D Redesign Program Instructions, which also implement the Inflation Reduction Act’s $2,000 annual out-of-pocket cap on prescription costs. That cap is the headline consumer protection of the redesign, shielding enrollees from catastrophic drug bills that can arise from high-cost specialty medications. But the deductible sits at the front end of the benefit, meaning enrollees in plans that charge the full $615 still pay that amount before most coverage begins.
Plans that set their deductible at $0 skip that barrier entirely, and CMS confirms that some plans already offer no deductible at all. The trade-off is that plans with lower deductibles often charge higher monthly premiums or use tighter formularies and utilization management tools. In 2026, with a hard ceiling on total out-of-pocket spending, the value of reducing that first-dollar exposure may look different to beneficiaries than it did in earlier years when catastrophic costs were open-ended.
The gap between a $615 deductible and a $0 deductible could drive enrollment decisions. Beneficiaries comparing plans during open enrollment will weigh the upfront savings of a zero-deductible option against monthly premium differences and expected medication needs. Someone who takes several maintenance drugs early in the year may value avoiding a large deductible, while a person who fills few prescriptions could decide a lower-premium plan with the full deductible is acceptable. If the Inflation Reduction Act’s out-of-pocket cap makes total annual costs more predictable, the deductible becomes a clearer differentiator between competing plans.
CMS confirms the $615 cap and what it covers
No Medicare drug plan may set a deductible above $615 in 2026, according to the agency’s official cost information. That ceiling applies to standalone Part D plans and Medicare Advantage plans with prescription drug coverage alike. Plans can charge less or nothing, but the $615 figure is the legal maximum for the standard benefit design.
CMS published the deductible alongside other updated benefit parameters through its Part D redesign guidance hub. The agency’s materials explain that the deductible applies only to covered Part D drugs and does not include premiums or costs for non-covered medications. Once an enrollee meets the deductible, they move into the main coverage phase, where they pay plan-specific copays or coinsurance until their total out-of-pocket spending reaches the new $2,000 cap.
The redesign also changes how costs are counted toward that cap. Manufacturer discounts in the catastrophic phase and plan liability are restructured so that beneficiaries hit the $2,000 threshold more straightforwardly than under the prior system, which relied on a mix of enrollee payments, plan payments, and manufacturer discounts in the coverage gap. CMS describes these changes as part of a broader set of Part D improvements aimed at affordability and transparency.
For beneficiaries, the key practical takeaway is that 2026 will combine a higher deductible with a firm ceiling on total spending. People who routinely spend more than $2,000 a year on covered prescriptions are likely to see meaningful protection against extreme costs, even if they must first satisfy the larger deductible. Those with lower drug spending may feel the deductible increase more acutely, particularly if they are enrolled in plans that adopt the maximum amount.
Advisers and plan counselors will need to help beneficiaries model their likely costs under different plan designs. That includes looking beyond the deductible to premiums, copays, coinsurance levels, and each plan’s formulary. Because the deductible is capped but optional, some insurers may use a lower or zero deductible as a marketing tool, while others may emphasize stable premiums and broad drug coverage. How beneficiaries respond to those trade-offs will shape the early years of the redesigned Part D program.
